Association of age, gender, and weight on maintenance dose of intravenous unfractionated heparin

American Journal of Hematology

Volumn 85, Issue 8, 2010, Pages 624-626

  Verma, Siddharth ^a   Kato, Shumei ^a   Blum, Ronald ^a   Shapira, Ilan ^a   Friedmann, Patricia ^a   Varma, Mala ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; HEPARIN; PROTEIN; ANTICOAGULANT AGENT; PLASMA PROTEIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BODY WEIGHT; COHORT ANALYSIS; CONTINUOUS INFUSION; FEMALE; GENDER; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; AGE; BLOOD; COMORBIDITY; LETTER; MIDDLE AGED; SEX DIFFERENCE; THROMBOPHILIA;

ACUTE CORONARY SYNDROME; AGE FACTORS; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; BLOOD PROTEINS; BODY WEIGHT; COHORT STUDIES; COMORBIDITY; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS; THROMBOPHILIA;

EID: 77955501093     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21751     Document Type: Article

References (22)

1. Hirsh J, Anand SS, Halperin JL, et al. Guide to anticoagulant therapy: Heparin: A statement for healthcare professionals from the American Heart Association. Circulation 2001;103:2994-3018.
2. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:141S-159S.
3. Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl 2002;41:391-412.
4. Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis. Lancet 2000;355:1936-1942.
5. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999;34:890-911.
6. Theroux P, Waters D, Qiu S, et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993;88: 2045-2048.
7. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:429S-456S.
8. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133: 454S-545S.
9. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 1993;119:874-881.
10. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-304.
11. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94S.
12. Hylek EM, Regan S, Henault LE, et al. Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. Arch Intern Med 2003;163:621-627.
13. Cosmi B, Fredenburgh JC, Rischke J, et al. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. Circulation 1997;95:118-124.
14. Manson L, Weitz JI, Podor TJ, et al. The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance. J Lab Clin Med 1997;130:649-655.
15. Young E, Prins M, Levine MN, et al. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992;67:639-643.
16. Young E, Wells P, Holloway S, et al. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994;71:300-304.
17. Zammit A, Pepper DS, Dawes J. Interaction of immobilised unfractionated and LMW heparins with proteins in whole human plasma. Thromb Haemost 1993;70:951-958.
18. Ignjatovic V, Furmedge J, Newall F, et al. Age-related differences in heparin response. Thromb Res 2006;118:741-745.
19. Monte S, Lyons G. In vitro evidence of gender-related heparin resistance. Int J Obstet Anesth 2004;13:91-94.
20. Hirsh J, van Aken WG, Gallus AS, et al. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976;53:691-695.
21. Boneu B, Caranobe C, Gabaig AM, et al. Evidence for a saturable mechanism of disappearance of standard heparin in rabbits. Thromb Res 1987;46: 835-844.
22. de Swart CA, Nijmeyer B, Roelofs JM, et al. Kinetics of intravenously administered heparin in normal humans. Blood 1982;60:1251-1258.